Thus, our study provided the first characterization of the role of HOXA-AS3 in mediating drug resistance, establishing HOXA-AS3 as a candidate drug target to develop more efficient cisplatin-based treatment for NSCLC. Here, HOXA-AS3 is linked to non-small cell lung carcinoma.